Search results for: opioid-use-disorder-mat-and-stigma-impact-stigma-drug-court-0

...Clinical Trials Network, will discuss recent trends in co-occurring methamphetamine use and opioid use disorder (OUD), including overdose fatalities. Participants will also learn about the treatment approaches to address this...

...protect people who are using MAT. Discrimination is also common because people in MAT frequently do not have the tools necessary to educate employers, landlords, courts, and others about MAT

...as those available for alcohol addiction, including naltrexone (ReVia®, Vivitrol®, Depade®), Disulfiram (Antabuse®), and Acamprosate Calcium (Campral®) Locating Physicians who Provide MAT MAT for Opioid

Stigma toward Naloxone: Racial-ethnic Differences and Implications for Opioid Overdose Response By Emily Pasman, PhD, LMSW Naloxone is a drug to prevent drug overdose and is now sold in pharmacies...

...that may include physical dependence, but requires other behavioral symptoms indicating loss of control over use, exacerbation of problems because of use, and continued use despite negative consequences

...Kukataa Teens and Opioids (Swahili) - Vijana na Opioid Tagalog (Filipino) Opioid Prevention Materials - Tagalog (Filipino) Mga Materyales sa Pag-iwas sa Opioid

In collaboration with the New England Association of Drug Court Professionals (NEADCP) and the Opioid Response Network of New England (ORN), we developed a second webinar that focused primarily on the impact of stigma on drug court participation in MAT. We discussed common challenges facing patients within the criminal justice population, including criminal thinking, underlying trauma, and stigma. We also discussed stigma with regard to both MAT and the criminal justice population, with special attention to three types of stigma: self-stigma, social stigma, and institutional stigma, including the reluctance to be involved in providing MAT services from an institutional standpoint. Further, we discussed the efficacy of MAT in these populations, as well as existing barriers, and how these relate to the three above-mentioned types of stigma.  A major point of emphasis was that MAT is highly efficacious regardless of whether a patient has a history of criminal involvement.

This webinar will focus primarily on the participant experience within the drug court system and using MAT as a treatment for opioid use disorder. We aim to discuss the challenges present within the criminal justice population, including criminal thinking, underlying trauma, and stigma. We will discuss stigma with regard to both MAT and the criminal justice population, with special attention to three types of stigma: Self-stigma, social stigma, and institutional stigma, including the reluctance to be involved in providing MAT services from an institutional standpoint. Further, we will discuss the efficacy of MAT in these populations, as well as existing barriers, and how these relate to the three above mentioned types of stigma. A driving take away point we hope to impress on attendees is that the evidence and efficacy of MAT for opioid use disorders is there and that the biology of a criminally involved person is the same as someone who is not.

...Drug Courts is a program that seeks the recovery of people with substance use disorders through a continuous and intensive judicial follow up. It applies the Therapeutic Justice Model, which...

...(Weber et al., 2021). For pregnant individuals with opioid use disorders (OUD), the stigma may be more intense and the hazards even greater, given the powerful effects of chronic opioid...

...ATTC Messenger March 2018: The Evolution of Federal Drug Policy And Its Impacts on Treatment for Opioid Use Disorder ATTC Messenger April 2018: Destroying Addiction Stigma Once and For All:...

...FAAN Richard Bottner, DHA, PA-C View Blog Episode 3 Barriers to Treatment for Opioid Use Disorder: Why Aren't Pharmacists Stocking Buprenorphine? Patients with opioid use disorder must be able to...

The New England ATTC, in partnership with the NEARCP, hosted the next webinar in a series of basic/universal TA sessions for criminal justice professionals titled “Incentives on a Dime”. This 1.5-hour session first focused on the science supporting the use of incentives and then took a deep dive into the creation, implementation, and delivery of incentives. Participants were provided with detailed handouts, a fully customized toolkit, and an array of new incentive-based skills.

...and Stimulant Use Disorders, with Roy Stein, MD In this episode (the first of two episodes about MI for opioid and stimulant use disorders), Glenn and Sebastian talk to Dr....

...have primarily focused on impacts of cocaine, methamphetamines, prescription drug misuse, and opioid use disorder. Discussions of alcohol use disorders have gone the way of the dinosaur

...professionalism of the Peer Support role have demonstrated the beneficial impacts to court participants, teams, and programs. This presentation is intended to support treatment court teams in understanding the value...

Dennis McCarty, PhD Kelsey C. Priest, MPH P. Todd Korthuis, MD, MPH Oregon Health & Science University OHSU-PSU School of Public Health Understanding the development of federal drug policy will aid clinicians in navigating the treatment constraints (often invisible) for their patients. There are

...the end of this module, participants will be able to: Identify the Scope of: Substance Use Disorders, Mental Health Disorders, and Co-Occurring Disorders Illicit Drug Use Cocaine & Methamphetamine